TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer (Adv. Healthcare Mater. 7/2025)
Year: 2025
Type: article
Abstract: Pathogen Mimetic Particles In article 2402966, Rita E. Serda and co-workers show endocytosis of Toll-like receptor (TLR) agonist-modified mesoporous silica particles by peritoneal myeloid cells. Activation of surface and endosomal TLRs activates myeloid cells, enhancing anti-cancer immunity. Art by Lorél Medina.
Source: Advanced Healthcare Materials
Authors: Ben Marwedel, Henning De May, Lauren Anderson, Lorél Y. Medina, Ellie Kennedy, Erica Flores, John O'Rourke, Marian Olewine, Irina Lagutina, Lillian Fitzpatrick, Fred Shultz, Donna F. Kusewitt, Eric Bartee, Sarah Adams, Achraf Noureddine, Rita E. Serda
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4408501645